drugset / Trial / NCT01338805

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805

Phase 2 Completed 56 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.

Timeline

Start
2011-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject selurampanel Small molecule 50 mg Oral
Subject selurampanel Small molecule 100 mg Oral
Subject selurampanel Small molecule 150 mg Oral

Indications